Logo
x

Search

Subscribe Now

BMS

BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

  • November 18, 2024
BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors

BMS’ Repotrectinib Gains the CHMP’s Positive Opinion to Treat Advanced ROS1+ NSCLC and NTRK+ Solid Tumors

  • November 15, 2024
PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

PharmaShots Weekly Snapshots (September 30 – October 04, 2024)

  • October 4, 2024
BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)

  • October 4, 2024
BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoriasis

BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoria...

  • September 30, 2024
BMS’ Cobenfy (Xanomeline and Trospium Chloride) Receives the US FDA Approval for Treating Schizophrenia

BMS’ Cobenfy (Xanomeline and Trospium Chloride) Receives the US FDA Approval for Treating Schizophrenia

  • September 27, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.